Taysha Gene Therapies, an early stage biotech developing AAV-based gene therapies for CNS disorders, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Founded ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback